

(FILE 'HOME' ENTERED AT 18:35:49 ON 10 FEB 2004)

FILE 'REGISTRY' ENTERED AT 18:36:02 ON 10 FEB 2004

L1 STRUCTURE UPLOADED

L2 96 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 18:36:46 ON 10 FEB 2004

L3 26 S L2

L4 2 S L3 AND (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE?) OR

L5 3629 S DIPYRIDAMOLE

FILE 'REGISTRY' ENTERED AT 18:48:40 ON 10 FEB 2004

L6 1 S DIPYRIDAMOLE/CN

FILE 'CAPLUS' ENTERED AT 18:48:53 ON 10 FEB 2004

L7 4162 S L6 OR L5

L8 0 S L7 AND L3

L9 870 S SILDENAFIL

L10 16 S L9 AND L3

FILE 'REGISTRY' ENTERED AT 18:49:43 ON 10 FEB 2004

L11 1 S SILDENAFIL/CN

FILE 'CAPLUS' ENTERED AT 18:49:51 ON 10 FEB 2004

L12 492 S L11

L13 889 S L12 OR L9

L14 19 S L13 AND L3

L15 20411 S TREAT? (40A) (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE

L16 1 S L15 AND L14

=> save all

ENTER NAME OR (END):l09927344/l

L# LIST L1-L16 HAS BEEN SAVED AS 'L09927344/L'

=> save l14

ENTER NAME OR (END):a09927344/a

ANSWER SET L14 HAS BEEN SAVED AS 'A09927344/A'

=> save l10\

ENTER L#, L# RANGE, ALL, OR (END):end

=> save l10

ENTER NAME OR (END):b09927344/a

ANSWER SET L10 HAS BEEN SAVED AS 'B09927344/A'

(FILE 'HOME' ENTERED AT 18:35:49 ON 10 FEB 2004)

FILE 'REGISTRY' ENTERED AT 18:36:02 ON 10 FEB 2004

L1 STRUCTURE UPLOADED
L2 96 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 18:36:46 ON 10 FEB 2004

L3 26 S L2
L4 2 S L3 AND (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE?) OR
L5 3629 S DIPYRIDAMOLE

FILE 'REGISTRY' ENTERED AT 18:48:40 ON 10 FEB 2004

L6 1 S DIPYRIDAMOLE/CN

FILE 'CAPLUS' ENTERED AT 18:48:53 ON 10 FEB 2004

L7 4162 S L6 OR L5
L8 0 S L7 AND L3
L9 870 S SILDENAFIL
L10 16 S L9 AND L3

FILE 'REGISTRY' ENTERED AT 18:49:43 ON 10 FEB 2004

L11 1 S SILDENAFIL/CN

FILE 'CAPLUS' ENTERED AT 18:49:51 ON 10 FEB 2004

L12 492 S L11
L13 889 S L12 OR L9
L14 19 S L13 AND L3
L15 20411 S TREAT? (40A) (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE
L16 1 S L15 AND L14
SAVE ALL L09927344/L
SAVE L14 A09927344/A
SAVE L10 B09927344/A

FILE 'USPATFULL' ENTERED AT 19:04:26 ON 10 FEB 2004

L17 30 S L2
L18 7 S L17 AND (WOUND? OR ULCER? OR DECUBITUS OR (PRESSURE SORE?) OR

=> save l18

ENTER NAME OR (END):c09927344/a

ANSWER SET L18 HAS BEEN SAVED AS 'C09927344/A'


=>

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:525913 CAPLUS
 DN 135:107336
 ED Entered STN: 20 Jul 2001
 TI Treatment of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors
 IN Wood, Ralph E.; Davies, Michael John; Siegel, Richard Lewis
 PA Pfizer Limited, UK; Pfizer Inc.
 SO PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001051042	A2	20010719	WO 2001-IB18	20010111
	WO 2001051042	A3	20020110		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	EP 1248623	A2	20021016	EP 2001-900568	20010111
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP 2003519652	T2	20030624	JP 2001-551466	20010111
	US 2003176442	A1	20030918	US 2003-169921	20030307
PRAI	GB 2000-561	A	20000111		
	WO 2001-IB18	W	20010111		


GI



AB This patent relates to the use of cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of diabetic **ulcers**, particularly diabetic foot **ulcers** (no data). I,

a sildenafil analog, was prepared in a multi-step sequence involving the amidation of 2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)-3-pyridinecarboxylic acid (preparation given) with 4-amino-3-ethyl-1H-pyrazole-5-carboxamide, addition of 1-bromo-2-methoxyethane to the pyrazole ring, and cyclization using potassium bis(trimethylsilyl)amide and EtOAc in EtOH. Examples of formulations are included.

- ST cyclic guanosine monophosphate phosphodiesterase inhibitor prepn diabetic **ulcer** treatment; cGMP PDE5 inhibitor prepn diabetic foot **ulcer** treatment
- IT 171599-83-0, Sildenafil citrate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (formulation component; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)
- IT 16250-08-1P, Pyridin-2-amino-5-sulfonic acid 247582-62-3P 247582-63-4P 247582-68-9P 247582-73-6P 264920-27-6P 350047-17-5P 350047-18-6P 350047-19-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)
- IT 139755-83-2P, Sildenafil **334826-98-1P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)
- IT 504-29-0, 2-Aminopyridine 5308-25-8, 1-Ethylpiperazine 6482-24-2, 1-Bromo-2-methoxyethane 215298-74-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)
- IT **334826-98-1P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)
- RN 334826-98-1 CAPLUS
- CN Piperazine, 1-[[[6-ethoxy-5-[3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridinyl]sulfonyl]-4-ethyl- (9CI)
 (CA INDEX NAME)



=> d hit, ibib .

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

TI **Treatment** of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors

AB This patent relates to the use of cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound **sildenafil**, for the **treatment** of diabetic **ulcers**, particularly diabetic foot **ulcers** (no data). I, a **sildenafil** analog, was prepared in a multi-step sequence involving the amidation of 2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)-3-pyridinecarboxylic acid (preparation given) with 4-amino-3-ethyl-1H-pyrazole-5-carboxamide, addition of 1-bromo-2-methoxyethane to the pyrazole ring, and cyclization using potassium bis(trimethylsilyl)amide and EtOAc in EtOH. Examples of formulations are included.

ST cyclic guanosine monophosphate phosphodiesterase inhibitor prepn diabetic **ulcer treatment**; cGMP PDE5 inhibitor prepn diabetic foot **ulcer treatment**

IT 171599-83-0, **Sildenafil** citrate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(formulation component; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for **treatment** of diabetic **ulcers**)

IT 16250-08-1P, Pyridin-2-amino-5-sulfonic acid 247582-62-3P 247582-63-4P 247582-68-9P 247582-73-6P 264920-27-6P 350047-17-5P 350047-18-6P 350047-19-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for **treatment** of diabetic **ulcers**)

IT 139755-83-2P, **Sildenafil** 334826-98-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for **treatment** of diabetic **ulcers**)

IT 504-29-0, 2-Aminopyridine 5308-25-8, 1-Ethylpiperazine 6482-24-2, 1-Bromo-2-methoxyethane 215298-74-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for **treatment** of diabetic **ulcers**)

ACCESSION NUMBER: 2001:525913 CAPLUS

DOCUMENT NUMBER: 135:107336

TITLE: **Treatment** of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors

INVENTOR(S): Wood, Ralph E.; Davies, Michael John; Siegel, Richard Lewis

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051042	A2	20010719	WO 2001-IB18	20010111
WO 2001051042	A3	20020110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1248623 A2 20021016 EP 2001-900568 20010111
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2003519652 T2 20030624 JP 2001-551466 20010111
 US 2003176442 A1 20030918 US 2003-169921 20030307
 PRIORITY APPLN. INFO.: GB 2000-561 A 20000111
 WO 2001-IB18 W 20010111

=>

L18 ANSWER 6 OF 7 USPATFULL on STN

DETD . . . inflammation, leukemia, pain, epilepsy, affective disorders, dementia and geriatric confusion, obesity and gastrointestinal disorders (especially diarrhoea and irritable bowel syndrome), wound healing (especially diabetic and venous ulcers and pressure sores), septic shock, the modulation of gastric acid secretion, the treatment of hyperreninaemia, cystic fibrosis, restenosis, diabetic complications and atherosclerosis. In.

DETD . . . an in house designed applicator. Basically, pieces of tubing (ID 3 mm, OD 4 mm) 10 cm in length were cut and attached to a 1 ml syringes. The syringes were each filled with a control gel (containing no active ingredient).

IT 58-22-0, Testosterone 71-58-9, Medroxyprogesterone acetate 520-85-4, Medroxyprogesterone 521-18-6, Dihydrotestosterone 37221-79-7, Vasoactive intestinal peptide 37221-79-7D, Vasoactive intestinal peptide, analogs 139755-83-2, Sildenafil 147676-53-7 171596-29-5, IC-351 215297-27-1 224785-90-4, Vardenafil 334826-98-1 334827-47-3 334827-59-7 335077-64-0 335077-70-8 389128-36-3

(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

ACCESSION NUMBER: 2002:99469 USPATFULL

TITLE: Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

INVENTOR(S): Barber, Christopher Gordon, Kent, UNITED KINGDOM
Cook, Andrew Simon, Kent, UNITED KINGDOM
Maw, Graham Nigel, Kent, UNITED KINGDOM
Pryde, David Cameron, Kent, UNITED KINGDOM
Stobie, Alan, Kent, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052370	A1	20020502
APPLICATION INFO.:	US 2001-893585	A1	20010628 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-16684	20000706
	GB 2001-1584	20010122
	US 2000-219100P	20000718 (60)
	US 2001-274957P	20010312 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 5141

CAS INDEXING IS AVAILABLE FOR THIS PATEN

L18 ANSWER 2 OF 7 USPATFULL on STN

SUMM . . . as burning pain, cutaneous hyperaesthesia, paraesthesias, lancinating pain, loss of pain and temperature sensation, loss of visceral pain and foot **ulceration**; ii) primarily large-fibre manifesting as loss of vibration sensation, loss of proprioception, loss of reflexes and slowed nerve conduction velocities; . . .

IT 16250-08-1P, 2-Aminopyridine-5-sulfonic acid 216394-05-7P,
3-Bromo-2-chloropyridine-5-sulfonyl chloride 247582-62-3P
247582-63-4P 247582-68-9P 247582-73-6P 254454-54-1P 264920-27-6P
334828-19-2P 334828-24-9P 334828-32-9P 334828-39-6P
334828-45-4P 335077-39-9P 335077-45-7P 335077-51-5P
335077-57-1P 335077-59-3P 335078-01-8P 335078-02-9P 335078-18-7P
(cGMP phosphodiesterase inhibitors for the treatment of neuropathy)

IT **334826-98-1P** 334827-47-3P **334827-59-7P** 335077-64-0P
335077-70-8P

(cGMP phosphodiesterase inhibitors for the treatment of neuropathy)

ACCESSION NUMBER: 2003:232581 USPATFULL

TITLE: Treatment of neuropathy

INVENTOR(S): Grossman, Eric B., Hastings-on-Hudson, NY, UNITED STATES

Koppiker, Nandan P., Canterbury, UNITED KINGDOM
Leichter, Steven B., Cataula, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003162782	A1	20030828
APPLICATION INFO.:	US 2002-206615	A1	20020726 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-692781, filed on 19 Oct 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-24958	19991021
	GB 2000-21520	20000901
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1012	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

TI Treatment of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors

AB This patent relates to the use of cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of diabetic **ulcers**, particularly diabetic foot **ulcers** (no data). I, a sildenafil analog, was prepared in a multi-step sequence involving the amidation of 2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)-3-pyridinecarboxylic acid (preparation given) with 4-amino-3-ethyl-1H-pyrazole-5-carboxamide, addition of 1-bromo-2-methoxyethane to the pyrazole ring, and cyclization using potassium bis(trimethylsilyl)amide and EtOAc in EtOH. Examples of formulations are included.

ST cyclic guanosine monophosphate phosphodiesterase inhibitor prepn diabetic **ulcer** treatment; cGMP PDE5 inhibitor prepn diabetic foot **ulcer** treatment

IT 171599-83-0, Sildenafil citrate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (formulation component; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT 16250-08-1P, Pyridin-2-amino-5-sulfonic acid 247582-62-3P 247582-63-4P 247582-68-9P 247582-73-6P 264920-27-6P 350047-17-5P 350047-18-6P 350047-19-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT 139755-83-2P, Sildenafil **334826-98-1P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

IT 504-29-0, 2-Aminopyridine 5308-25-8, 1-Ethylpiperazine 6482-24-2, 1-Bromo-2-methoxyethane 215298-74-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of pyrazolo[4,3-d]pyrimidin-7-one cGMP PDE5 inhibitors for treatment of diabetic **ulcers**)

ACCESSION NUMBER: 2001:525913 CAPLUS

DOCUMENT NUMBER: 135:107336

TITLE: Treatment of diabetic **ulcers** with pyrazolo[4,3-d]pyrimidine-7-one cGMP PDE5 inhibitors

INVENTOR(S): Wood, Ralph E.; Davies, Michael John; Siegel, Richard Lewis

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 18 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051042	A2	20010719	WO 2001-IB18	20010111
WO 2001051042	A3	20020110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,


YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1248623 A2 20021016 EP 2001-900568 20010111
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2003519652 T2 20030624 JP 2001-551466 20010111
 US 2003176442 A1 20030918 US 2003-169921 20030307
 PRIORITY APPLN. INFO.: GB 2000-561 A 20000111
 WO 2001-IB18 W 20010111

=>

=>
Uploading C:\Program Files\Stnexp\Queries\09927344.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 exa ful
FULL SEARCH INITIATED 15:25:09
FULL SCREEN SEARCH COMPLETED - 18 TO ITERATE


100.0% PROCESSED 18 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L2 1 SEA EXA FUL L1

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 334826-98-1 REGISTRY
CN Piperazine, 1-[[6-ethoxy-5-[3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridinyl]sulfonyl]-4-ethyl- (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN 2-(Methoxyethyl)-5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
CN 5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
FS 3D CONCORD
MF C23 H33 N7 O5 S

CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus

=> d 1-2 hit, ibib

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

IT Foot

(diabetic foot **ulcer**; kit for reducing aching caused by phosphodiesterase V inhibitors)

IT **Ulcer**

(diabetic **ulcers**; kit for reducing aching caused by phosphodiesterase V inhibitors)

IT 139755-83-2, Sildenafil 147676-53-7 171596-29-5, Tadalafil
215297-27-1 224785-90-4, Vardenafil 247580-98-9 **334826-98-1**
335077-70-8

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(kit for reducing aching caused by phosphodiesterase V inhibitors)

ACCESSION NUMBER: 2003:450774 CAPLUS

DOCUMENT NUMBER: 139:17600

TITLE: Kit for reducing aching caused by phosphodiesterase V (PDE5) inhibitors

INVENTOR(S): Abel, Samantha; Ellis, Peter

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: Eur. Pat. Appl., 18 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1317924	A1	20030611	EP 2002-258123	20021126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2003047588	A1	20030612	WO 2002-IB4933	20021122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003192614	A2	20030709	JP 2002-349628	20021202
US 2003124150	A1	20030703	US 2002-310608	20021205
PRIORITY APPLN. INFO.:				
GB 2001-29274 A 20011206				
US 2002-355286P P 20020208				
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5 sss ful

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 15:32:59
FULL SCREEN SEARCH COMPLETED - 390 TO ITERATE

100.0% PROCESSED 390 ITERATIONS 96 ANSWERS
SEARCH TIME: 00.00.01

L6 96 SEA SSS FUL L5

L7 26 L6